scholarly journals Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

2016 ◽  
Vol 176 (5) ◽  
pp. 783-795 ◽  
Author(s):  
Noopur S. Raje ◽  
Philippe Moreau ◽  
Evangelos Terpos ◽  
Lotfi Benboubker ◽  
Norbert Grząśko ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Phase 2 ◽  
B Cell Activating Factor ◽  
Phase 2 Study ◽  
Previously Treated

scholarly journals Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

2019 ◽  
Vol 60 (8) ◽  
pp. 1972-1977 ◽  
Author(s):  
Farrukh T. Awan ◽  
Michael J. Thirman ◽  
Dipti Patel-Donnelly ◽  
Sarit Assouline ◽  
Arati V. Rao ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Cell Receptor ◽  
B Cell Receptor ◽  
Lymphocytic Leukemia ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Previously Treated

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document